Latest On Allergy Therapeutics plc (AGYTF):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2021-09-23 21:24 EST | News | Allergy Therapeutics reports FY results | N/A |  |
| 2021-03-05 10:21 EST | Financials | Company financials have been released. | Neutral | |
| 2020-12-04 06:37 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-27 01:04 EST | Financials | Company financials have been released. | Neutral | |
| 2020-10-08 21:26 EST | Financials | Company financials have been released. | Neutral | |
| 2020-10-04 15:42 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-26 16:49 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-25 07:38 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-17 09:28 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-31 08:41 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-14 12:54 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-06 16:37 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-04 19:55 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-31 12:17 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-31 04:47 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 20:55 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 08:42 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 01:01 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-28 15:57 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-27 16:35 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-23 21:26 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-09 12:45 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-09 07:45 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-03 07:23 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-02 23:49 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-02 07:23 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-01 20:25 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-01 04:16 EST | Financials | Company financials have been released. | Neutral | |
About Allergy Therapeutics plc (AGYTF):
Allergy Therapeutics plc engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies, particularly to grasses, weeds, and trees, as well as diagnostics. Its products include Pollinex, Pollinex Quattro, Oralvac, Acarovac Plus, Acarovac MPL, Venomil, Synbiotics, Penicillin Diagnostics, and Peanut. The company also develops allergy vaccines for grass, tree, and house dust mite, as well as peanut allergy vaccines. It operates in Central Europe, Southern Europe, the United Kingdom, and internationally. Allergy Therapeutics plc was incorporated in 2004 and is headquartered in Worthing, the United Kingdom.
General
- Name Allergy Therapeutics plc
- Symbol AGYTF
- Type Common Stock
- Exchange PINK
- Currency USD
- Country USA
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- Full Time Employees 600
- Fiscal Year EndJune
- Web URLhttp://www.allergytherapeutics.com
View More
Valuation
- Trailing PE 0.01
- Price/Sales (Trailing 12 Mt.) 1.51
- Price/Book (Most Recent Quarter) 2.57
- Enterprise Value Revenue 1.76
- Enterprise Value EBITDA 11.01
View More
Financials
- Most Recent Quarter 2020-12-31
- Profit Margin 8%
- Return on Assets 5%
- Return on Equity 12%
- Revenue Per Share $0
- Gross Profit 58 million
- Quarterly Earnings Growth 7.1%
View More
Highlights
- Market Capitalization 202.64 million
View More
Share Statistics
- Shares Outstanding 640.79 million
- Shares Float 359.34 million
- % Held by Insiders 8635%
- % Held by Institutions 11.54%
View More
Technicals
- Beta 1.63
- 52 Week High $0.35
- 50 Day Moving Average 0.26
- 200 Day Moving Average 0.18
View More
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
View More
Allergy Therapeutics plc (AGYTF) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Allergy Therapeutics plc (AGYTF) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-09-30 | 2020-12-31 | $N/A | $0.02 | $0.00 | |
| 2020-06-30 | 2020-09-30 | $N/A | $0.01 | $0.00 | |
| 2020-03-31 | 2020-06-30 | $N/A | -$0.01 | $0.00 | |
| 2019-12-31 | 2020-03-31 | $25.24 million | -$0.01 | $0.00 | |
| 2019-09-30 | 2019-12-31 | $25.24 million | $0.02 | $0.00 | |
| 2019-06-30 | 2019-09-30 | $13.5 million | $0.01 | $0.00 | |
| 2019-03-31 | 2019-06-30 | $13.5 million | -$0.01 | $0.00 | |
| 2018-12-31 | 2019-03-31 | $23.36 million | -$0.01 | $0.00 | |
| 2018-09-30 | 2018-12-31 | $23.36 million | $0.01 | $0.00 | |
| 2018-06-30 | 2018-09-30 | $13.05 million | $0.01 | $0.00 | |
| 2018-03-31 | 2018-06-30 | $13.05 million | -$0.02 | $0.00 | |
| 2017-12-31 | 2018-03-31 | $21.12 million | -$0.02 | $0.00 | |
| 2017-09-30 | 2017-12-31 | $21.12 million | $0.01 | $0.00 | |
| 2017-06-30 | 2017-09-30 | $11.86 million | $0.01 | $0.00 | |
| 2017-03-31 | 2017-06-30 | $11.86 million | -$0.01 | $0.00 | |
| 2016-12-31 | 2017-03-31 | -$0.01 | $0.00 | ||
| 2016-09-30 | 2016-12-31 | $0.01 | $0.00 | ||
| 2016-06-30 | 2016-09-30 | $0.01 | $0.00 | ||
| 2016-03-31 | 2016-06-30 | -$0.02 | $0.00 | ||
| 2015-12-31 | 2016-03-31 | -$0.02 | $0.00 | ||
| 2015-09-30 | 2015-12-31 | $0.00 | $0.00 | ||
| 2015-06-30 | 2015-09-30 | $0.00 | $0.00 | ||
| 2015-03-31 | 2015-06-30 | -$0.01 | $0.00 | ||
| 2014-12-31 | 2015-03-31 | -$0.01 | $0.00 | ||
| 2014-09-30 | 2014-12-31 | $0.01 | $0.00 | ||
| 2014-06-30 | 2014-09-30 | $0.01 | $0.00 | ||
| 2014-03-31 | 2014-06-30 | -$0.01 | $0.00 | ||
| 2013-12-31 | 2014-03-31 | -$0.01 | $0.00 | ||
| 2013-09-30 | 2013-12-31 | $0.01 | $0.00 | ||
| 2013-06-30 | 2013-09-30 | $0.01 | $0.00 | ||
| 2013-03-31 | 2013-06-30 | -$0.01 | $0.00 | ||
| 2012-12-31 | 2013-03-31 | -$0.01 | $0.00 | ||
| 2012-09-30 | 2012-12-31 | $0.01 | $0.00 | ||
| 2012-06-30 | 2012-09-30 | $0.01 | $0.00 | ||
| 2012-03-31 | 2012-06-30 | -$0.02 | $0.00 | ||
| 2011-12-31 | 2012-03-31 | -$0.02 | $0.00 | ||
| 2011-09-30 | 2011-12-31 | $0.02 | $0.00 | ||
| 2011-06-30 | 2011-09-30 | $0.02 | $0.00 | ||
| 2011-03-31 | 2011-06-30 | -$0.02 | $0.00 | ||
| 2010-12-31 | 2011-03-31 | -$0.02 | $0.00 | ||
| 2010-09-30 | 2010-12-31 | $0.01 | $0.00 |
Allergy Therapeutics plc (AGYTF) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Research Development | N/A | N/A | N/A | N/A | -963500 |
| Income Before Tax | N/A | N/A | N/A | N/A | 7.93 million |
| Selling General Administrative | N/A | N/A | N/A | N/A | 10.9 million |
| Gross Profit | N/A | N/A | N/A | N/A | 19.53 million |
| Ebit | N/A | N/A | N/A | N/A | 9.6 million |
| Operating Income | N/A | N/A | N/A | N/A | 9.6 million |
| Income Tax Expense | 317000 | 317000 | 217000 | 217000 | 289500 |
| Total Revenue | N/A | N/A | N/A | N/A | 25.24 million |
| Cost of Revenue | N/A | N/A | N/A | N/A | 5.71 million |
| Total Other Income Expense Net | N/A | N/A | N/A | N/A | -1.67 million |
| Net Income From Continuing Operations | N/A | N/A | N/A | N/A | 7.64 million |
| Net Income Applicable to Common Shares | 7.47 million | 7.47 million | -4.11 million | -4.11 million | 7.64 million |
Cash Flow:
| Date | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Oct 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Investments | N/A | N/A | N/A | N/A | N/A |
| Change to Liabilities | 664000 | 664000 | -1.86 million | -1.86 million | -1.86 million |
| Total Cash Flow from Investing Activities | -754500 | -754500 | -500000 | -500000 | -500000 |
| Net Borrowings | 461000 | 461000 | -516500 | -516500 | -516500 |
| Total Cash Flow from Financial Activities | N/A | N/A | -516500 | N/A | -516500 |
| Change to Operating Activities | N/A | N/A | N/A | N/A | N/A |
| Change in Cash | N/A | N/A | 6.14 million | N/A | 6.14 million |
| Total Cash from Operating Activities | -1.29 million | -1.29 million | 7.29 million | 7.29 million | 7.29 million |
| Depreciation | N/A | N/A | 961000 | N/A | 961000 |
| Other Cash Flow from Investing Activities | -6500 | -6500 | 25500 | 25500 | 25500 |
| Change to Inventory | N/A | N/A | 285500 | N/A | 285500 |
| Change to Account Receivables | N/A | N/A | -89000 | N/A | -89000 |
| Other Cash Flow from Financing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Net Income | -138000 | -138000 | 362500 | 362500 | 362500 |
| Capital Expenditures | N/A | N/A | 499000 | N/A | 499000 |
Balance Sheet:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Total Liabailities | N/A | N/A | N/A | N/A | 36.72 million |
| Total Stockholder Equity | N/A | N/A | N/A | N/A | 51.2 million |
| Other Current Liabilities | N/A | N/A | N/A | N/A | N/A |
| Total Assets | N/A | N/A | N/A | N/A | 87.92 million |
| Common Stock | 651000 | 651000 | 637000 | 637000 | 646000 |
| Other Current Assets | 2000 | 2000 | N/A | N/A | 324000 |
| Retained Earnings | -97.99 million | -97.99 million | -112.96 million | -112.96 million | -105.59 million |
| Other Liabilities | 14.13 million | 14.13 million | 14.3 million | 14.3 million | 12.85 million |
| Other Assets | 5.93 million | 5.93 million | 5.9 million | 5.9 million | 5.48 million |
| Cash | N/A | N/A | N/A | N/A | 39.73 million |
| Total Current Liabilities | 16.35 million | 16.35 million | N/A | N/A | 15.02 million |
| Other Stockholder Equity | 43.49 million | 43.49 million | 43.53 million | 43.53 million | 43.57 million |
| Property, Plant & Equipment | 19.5 million | 19.5 million | 20.42 million | 20.42 million | 20.34 million |
| Total Current Assets | 69.16 million | 69.16 million | N/A | N/A | 57.53 million |
| Long Term Investments | N/A | N/A | N/A | N/A | N/A |
| Net Tangible Assets | 54.31 million | 54.31 million | 39.05 million | 39.05 million | 46.63 million |
| Short Term Investments | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | 1.32 million |
| Inventory | 10.09 million | 10.09 million | N/A | N/A | 8.72 million |
| Accounts Payable | 14.15 million | 14.15 million | N/A | N/A | 12.9 million |
Allergy Therapeutics plc (AGYTF) Chart:
Allergy Therapeutics plc (AGYTF) News:
Below you will find a list of latest news for Allergy Therapeutics plc (AGYTF) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Allergy Therapeutics plc (AGYTF) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Allergy Therapeutics plc (AGYTF) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|